<DOC>
	<DOCNO>NCT01125917</DOCNO>
	<brief_summary>The purpose extension phase evaluate long-term safety tolerability buprenorphine transdermal system ( BTDS ) . Subjects begin extension phase BTDS 5 mcg/h may up- down-titrate dose [ BTDS 20 microgram ( mcg ) / hour ( h ) ] depend adequate pain relief tolerability .</brief_summary>
	<brief_title>Safety BTDS Subjects With Low Back Pain : A 52-Week Extension Phase BUP3015</brief_title>
	<detailed_description>Buprenorphine synthetic opioid analgesic 25 year international clinical experience indicate safe effective variety therapeutic situation relief moderate severe pain .</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Subjects complete visit doubleblind phase study drug , subject discontinue study drug due lack therapeutic effect doubleblind phase complete visit doubleblind phase study drug eligible enroll extension phase . For subject enter extension , 4 electrocardiogram ( ECGs ) require entry none collect prior randomization BTDS 20 . NOTE : Subjects 1 QT data correct heart rate use Fridericia formula ( QTcF ) interval â‰¥ 500 millisecond ( msec ) would discontinue extension phase Subjects require longacting opioid analgesic [ twicedaily dose every ( q ) 24 hour ( h ) q12h drug ] transdermal fentanyl extension phase discontinue study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Low back pain</keyword>
	<keyword>Opioid</keyword>
	<keyword>Transdermal</keyword>
</DOC>